Results 161 to 170 of about 2,744,211 (203)

Estrogen prevents anti-tumor effects of Zoledronic acid in breast cancer through the NK and CD8+T cell PD-1/PD-L1 axes

open access: yes
George C   +14 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Zoledronic acid

Expert Opinion on Drug Safety, 2010
Both bone metastases and fragility fractures due to bone loss result in considerable morbidity affecting quality of life and independence as well as placing complex demands on healthcare resources. Zoledronic acid is a widely used intravenous bisphosphonate that reduces this skeletal morbidity in both benign and malignant conditions.The incidence ...
Robert, Coleman   +6 more
  +6 more sources

Zoledronic Acid

Drugs, 2001
Zoledronic acid (zoledronate) is a new generation bisphosphonate that inhibits osteoclast bone resorption. It was much more potent than other bisphosphonates at inhibiting 1,25-dihydroxyvitamin D3-induced hypercalcaemia in a rat model and calcium release in vitro.
S M, Cheer, S, Noble
openaire   +2 more sources

Zoledronic Acid and Angiogenesis

Clinical Cancer Research, 2007
To the Editors: In a recent issue of Clinical Cancer Research , Santini and co-workers ([1][1]) assert that zoledronic acid (ZA) may inhibit several antiangiogenic-related cascades and its metronomic administration could represent a new potential therapy targeting the endothelial-tumor ...
Gianluigi, Ferretti   +6 more
openaire   +2 more sources

Fracture Risk and Zoledronic Acid Therapy in Men With Osteoporosis [PDF]

open access: yesNew England Journal of Medicine, 2012
peer reviewedBACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. METHODS: In
Hans Peter Dimai   +2 more
exaly   +3 more sources

The safety of zoledronic acid

Expert Opinion on Drug Safety, 2007
Zoledronic acid has been marketed for the past 5 years for the treatment of hypercalcemia of malignancy and malignant bone disease in patients with multiple myeloma or a broad range of solid tumors. The safety profile of zoledronic acid in this patient population is well established from the databases of several large, randomized, Phase III trials and ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy